Skip to main content
Top
Published in: Endocrine 2/2022

24-05-2022 | Radiotherapy | Original Article

Risk stratification in patients with anaplastic thyroid carcinoma: role of age

Authors: Mingjun Wang, Tao Wei, Rixiang Gong, Jingqiang Zhu, Zhihui Li

Published in: Endocrine | Issue 2/2022

Login to get access

Abstract

Background

Thyroid carcinoma is the only cancer that regards age as an important predictor of thyroid cancer-specific survival (CSS). While the 8th American Joint Committee on Cancer (AJCC) staging system raised the age cutoff from 45 to 55 years for differentiated thyroid carcinoma (DTC) to more accurately predict the prognosis, there is no new information regarding the role of age in the prognosis of anaplastic thyroid carcinoma (ATC). The aim of this study was to determine the optimal age cutoff values for mortality risk stratification in ATC patients. Furthermore, a nomogram to predict ATC CSS was developed in each age group.

Methods

Patients diagnosed with ATC between 2004 and 2015 were identified in the Surveillance, Epidemiology, and End Results (SEER) database. After applying inclusion and exclusion criteria, a total of 1140 patients were enrolled as cohort 1 to describe the characteristics of ATC, while a total of 556 patients were included as cohort 2 to determine age cutoff values for risk stratification by X-tile program. Training set and testing set were randomly generated to develop and validate a predictive nomogram of CSS in each age group.

Results

The 6-month, 1-year, and 2-year survival was 27.6%, 15.1%, and 6.2%, respectively, in cohort 1. X-tile program results showed that the optimal age cutoff values for mortality risk stratification were 65 and 85 years old (p < 0.001). Distant metastasis was independently associated with CSS in patients younger than 85 years old, and these patients benefited more from complete resection of the tumor and radiotherapy/chemotherapy. However, no predictors of CSS were identified in patients over 85 years old, and interventions (surgery, radiotherapy, and chemotherapy) targeting ATC had little role in disease control in these patients. The nomogram was developed and validated based on the independent CSS predictors in each age group. The C-index values of the training set and testing set were 0.735 [95% CI, 0.696–0.774] and 0.733 [95% CI, 0.663–0.804] for CSS in patients of ≤64 years old, while the values were 0.767 [95% CI, 0.730–0.804] and 0.783 [95% CI, 0.718–0.848] in patients of 65–84 years old. All of the C-index values were larger than 0.7, which showed acceptable prediction performance of the nomograms.

Conclusions

Age can be used as an auxiliary stratification factor of prognosis in ATC patients. The survival may be improved in patients younger than 85 years old if combination therapy (surgery, radiotherapy, and chemotherapy) was indicated and applicable, while no optimal therapeutic strategy was determined in patients older than 85 years old. The established nomograms can provide good prediction of CSS according to age group.
Appendix
Available only for authorised users
Literature
1.
go back to reference M.B. Amin, S.B. Edge, F.L. Greene, D.R. Byrd, R.K. Brookland, M. K. Washington, J.E. Gershenwald, C.C. Compton, K.R. Hess, D.C. Sullivan, J.M. Jessup, J.D. Brierley, L.E. Gaspar, R.L. Schilsky, C.M. Balch, D.P. Winchester, E.A. Asare, M. Madera, D.M. Gress, L.R. Meyer, AJCC Cancer Staging Manual. 8th ed. New York: Springer (2017) M.B. Amin, S.B. Edge, F.L. Greene, D.R. Byrd, R.K. Brookland, M. K. Washington, J.E. Gershenwald, C.C. Compton, K.R. Hess, D.C. Sullivan, J.M. Jessup, J.D. Brierley, L.E. Gaspar, R.L. Schilsky, C.M. Balch, D.P. Winchester, E.A. Asare, M. Madera, D.M. Gress, L.R. Meyer, AJCC Cancer Staging Manual. 8th ed. New York: Springer (2017)
2.
go back to reference N.D. Perrier, J.D. Brierley, R.M. Tuttle, Differentiated and anaplastic thyroid carcinoma: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin. 68(1), 55–63 (2018)CrossRef N.D. Perrier, J.D. Brierley, R.M. Tuttle, Differentiated and anaplastic thyroid carcinoma: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin. 68(1), 55–63 (2018)CrossRef
3.
go back to reference K.C. Bible, E. Kebebew, J. Brierley, J.P. Brito, M.E. Cabanillas, T.J. Clark Jr., A. Di Cristofano, R. Foote, T. Giordano, J. Kasperbauer, K. Newbold, Y.E. Nikiforov, G. Randolph, M.S. Rosenthal, A.M. Sawka, M. Shah, A. Shaha, R. Smallridge, C.K. Wong-Clark, 2021 American Thyroid Association Guidelines for management of patients with anaplastic thyroid cancer. Thyroid 31(3), 337–386 (2021)CrossRef K.C. Bible, E. Kebebew, J. Brierley, J.P. Brito, M.E. Cabanillas, T.J. Clark Jr., A. Di Cristofano, R. Foote, T. Giordano, J. Kasperbauer, K. Newbold, Y.E. Nikiforov, G. Randolph, M.S. Rosenthal, A.M. Sawka, M. Shah, A. Shaha, R. Smallridge, C.K. Wong-Clark, 2021 American Thyroid Association Guidelines for management of patients with anaplastic thyroid cancer. Thyroid 31(3), 337–386 (2021)CrossRef
4.
go back to reference B. Lin, H. Ma, M. Ma, Z. Zhang, Z. Sun, I.Y. Hsieh, O. Okenwa, H. Guan, J. Li, W. Lv, The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis. Am. J. Transl. Res. 11(9), 5888–5896 (2019)PubMedPubMedCentral B. Lin, H. Ma, M. Ma, Z. Zhang, Z. Sun, I.Y. Hsieh, O. Okenwa, H. Guan, J. Li, W. Lv, The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis. Am. J. Transl. Res. 11(9), 5888–5896 (2019)PubMedPubMedCentral
5.
go back to reference E. Kebebew, F.S. Greenspan, O.H. Clark, K.A. Woeber, A. McMillan, Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103(7), 1330–1335 (2005)CrossRef E. Kebebew, F.S. Greenspan, O.H. Clark, K.A. Woeber, A. McMillan, Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103(7), 1330–1335 (2005)CrossRef
6.
go back to reference N. Onoda, I. Sugitani, K.I. Ito, A. Suzuki, T. Higashiyama, T. Fukumori, N. Suganuma, K. Masudo, H. Nakayama, A. Uno, K. Yane, S. Yoshimoto, A. Ebina, Y. Kawasaki, S. Maeda, M. Iwadate, S. Suzuki, Evaluation of the 8th Edition TNM Classification for Anaplastic Thyroid Carcinoma. Cancers 12(3), 552 (2020)CrossRef N. Onoda, I. Sugitani, K.I. Ito, A. Suzuki, T. Higashiyama, T. Fukumori, N. Suganuma, K. Masudo, H. Nakayama, A. Uno, K. Yane, S. Yoshimoto, A. Ebina, Y. Kawasaki, S. Maeda, M. Iwadate, S. Suzuki, Evaluation of the 8th Edition TNM Classification for Anaplastic Thyroid Carcinoma. Cancers 12(3), 552 (2020)CrossRef
7.
go back to reference W. Gui, W. Zhu, W. Lu, C. Shang, F. Zheng, X. Lin, H. Li, Development and validation of a prognostic nomogram to predict overall survival and cancer-specific survival for patients with anaplastic thyroid carcinoma. PeerJ 8, e9173 (2020)CrossRef W. Gui, W. Zhu, W. Lu, C. Shang, F. Zheng, X. Lin, H. Li, Development and validation of a prognostic nomogram to predict overall survival and cancer-specific survival for patients with anaplastic thyroid carcinoma. PeerJ 8, e9173 (2020)CrossRef
8.
go back to reference A.M. Roche, S.A. Fedewa, L.L. Shi, A.Y. Chen, Treatment and survival vary by race/ethnicity in patients with anaplastic thyroid cancer. Cancer 124(8), 1780–1790 (2018)CrossRef A.M. Roche, S.A. Fedewa, L.L. Shi, A.Y. Chen, Treatment and survival vary by race/ethnicity in patients with anaplastic thyroid cancer. Cancer 124(8), 1780–1790 (2018)CrossRef
9.
go back to reference M. Pereira, V.L. Williams, J. Hallanger Johnson, P. Valderrabano, Thyroid cancer incidence trends in the United States: association with changes in professional guideline recommendations. Thyroid 30(8), 1132–1140 (2020)CrossRef M. Pereira, V.L. Williams, J. Hallanger Johnson, P. Valderrabano, Thyroid cancer incidence trends in the United States: association with changes in professional guideline recommendations. Thyroid 30(8), 1132–1140 (2020)CrossRef
10.
go back to reference R.L. Camp, M. Dolled-Filhart, D.L. Rimm, X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer Res. 10(21), 7252–7259 (2004)CrossRef R.L. Camp, M. Dolled-Filhart, D.L. Rimm, X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer Res. 10(21), 7252–7259 (2004)CrossRef
11.
go back to reference D.P. Byar, S.B. Green, P. Dor, E.D. Williams, J. Colon, H.A. van Gilse, M. Mayer, R.J. Sylvester, M. van Glabbeke, A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur. J. Cancer 15(8), 1033–1041 (1979)CrossRef D.P. Byar, S.B. Green, P. Dor, E.D. Williams, J. Colon, H.A. van Gilse, M. Mayer, R.J. Sylvester, M. van Glabbeke, A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur. J. Cancer 15(8), 1033–1041 (1979)CrossRef
12.
go back to reference I.D. Hay, E.J. Bergstralh, J.R. Goellner, J.R. Ebersold, C.S. Grant, Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114(6), 1050–1057 (1993)PubMed I.D. Hay, E.J. Bergstralh, J.R. Goellner, J.R. Ebersold, C.S. Grant, Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114(6), 1050–1057 (1993)PubMed
13.
go back to reference B. Cady, R. Rossi, An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104(6), 947–953 (1988)CrossRef B. Cady, R. Rossi, An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104(6), 947–953 (1988)CrossRef
14.
go back to reference A.R. Shaha, T.R. Loree, J.P. Shah, Intermediate-risk group for differentiated carcinoma of thyroid. Surgery 116(6), 1036–1040 (1994)PubMed A.R. Shaha, T.R. Loree, J.P. Shah, Intermediate-risk group for differentiated carcinoma of thyroid. Surgery 116(6), 1036–1040 (1994)PubMed
15.
go back to reference O.M.M. Beahrs, American Joint Committee on Cancer Manual for Staging of Cancer, 2nd edn. (Lippincott, Philadelphia, PA, 1983) O.M.M. Beahrs, American Joint Committee on Cancer Manual for Staging of Cancer, 2nd edn. (Lippincott, Philadelphia, PA, 1983)
16.
go back to reference I.J. Nixon, L.Y. Wang, J.C. Migliacci, A. Eskander, M.J. Campbell, A. Aniss, L. Morris, F. Vaisman, R. Corbo, D. Momesso, M. Vaisman, A. Carvalho, D. Learoyd, W.D. Leslie, R.W. Nason, D. Kuk, V. Wreesmann, L. Morris, F.L. Palmer, I. Ganly, S.G. Patel, B. Singh, R.M. Tuttle, A.R. Shaha, M. Gonen, K.A. Pathak, W.T. Shen, M. Sywak, L. Kowalski, J. Freeman, N. Perrier, J.P. Shah, An international multi-institutional validation of age 55 years as a cutoff for risk stratification in the AJCC/UICC staging system for well-differentiated thyroid cancer. Thyroid 26(3), 373–380 (2016)CrossRef I.J. Nixon, L.Y. Wang, J.C. Migliacci, A. Eskander, M.J. Campbell, A. Aniss, L. Morris, F. Vaisman, R. Corbo, D. Momesso, M. Vaisman, A. Carvalho, D. Learoyd, W.D. Leslie, R.W. Nason, D. Kuk, V. Wreesmann, L. Morris, F.L. Palmer, I. Ganly, S.G. Patel, B. Singh, R.M. Tuttle, A.R. Shaha, M. Gonen, K.A. Pathak, W.T. Shen, M. Sywak, L. Kowalski, J. Freeman, N. Perrier, J.P. Shah, An international multi-institutional validation of age 55 years as a cutoff for risk stratification in the AJCC/UICC staging system for well-differentiated thyroid cancer. Thyroid 26(3), 373–380 (2016)CrossRef
17.
go back to reference K. Kim, J.H. Kim, I.S. Park, Y.S. Rho, G.H. Kwon, D.J. Lee, The updated AJCC/TNM staging system for papillary thyroid cancer (8th edition): from the perspective of genomic analysis. World J. Surg. 42(11), 3624–3631 (2018)CrossRef K. Kim, J.H. Kim, I.S. Park, Y.S. Rho, G.H. Kwon, D.J. Lee, The updated AJCC/TNM staging system for papillary thyroid cancer (8th edition): from the perspective of genomic analysis. World J. Surg. 42(11), 3624–3631 (2018)CrossRef
18.
go back to reference M. de Ridder, E. Nieveen van Dijkum, A. Engelsman, E. Kapiteijn, H.J. Klumpen, C.R.N. Rasch, Anaplastic thyroid carcinoma: a nationwide cohort study on incidence, treatment and survival in the Netherlands over 3 decades. Eur. J. Endocrinol. 183(2), 203–209 (2020)CrossRef M. de Ridder, E. Nieveen van Dijkum, A. Engelsman, E. Kapiteijn, H.J. Klumpen, C.R.N. Rasch, Anaplastic thyroid carcinoma: a nationwide cohort study on incidence, treatment and survival in the Netherlands over 3 decades. Eur. J. Endocrinol. 183(2), 203–209 (2020)CrossRef
19.
go back to reference G.B. Hvilsom, S.C. Londero, C.H. Hahn, S. Schytte, H.B. Pedersen, P. Christiansen, K. Kiss, S.R. Larsen, M.L. Jespersen, G. Lelkaitis, C. Godballe, Anaplastic thyroid carcinoma in Denmark 1996-2012: a national prospective study of 219 patients. Cancer Epidemiol. 53, 65–71 (2018)CrossRef G.B. Hvilsom, S.C. Londero, C.H. Hahn, S. Schytte, H.B. Pedersen, P. Christiansen, K. Kiss, S.R. Larsen, M.L. Jespersen, G. Lelkaitis, C. Godballe, Anaplastic thyroid carcinoma in Denmark 1996-2012: a national prospective study of 219 patients. Cancer Epidemiol. 53, 65–71 (2018)CrossRef
20.
go back to reference J.R. Wang, M.E. Zafereo, R. Dadu, R. Ferrarotto, N.L. Busaidy, C. Lu, S. Ahmed, M.K. Gule-Monroe, M.D. Williams, E.M. Sturgis, R.P. Goepfert, N.D. Gross, S.Y. Lai, G.B. Gunn, J. Phan, D.I. Rosenthal, C.D. Fuller, W.H. Morrison, P. Iyer, M.E. Cabanillas, Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF(V600E)-mutated anaplastic thyroid carcinoma. Thyroid 29(8), 1036–1043 (2019)CrossRef J.R. Wang, M.E. Zafereo, R. Dadu, R. Ferrarotto, N.L. Busaidy, C. Lu, S. Ahmed, M.K. Gule-Monroe, M.D. Williams, E.M. Sturgis, R.P. Goepfert, N.D. Gross, S.Y. Lai, G.B. Gunn, J. Phan, D.I. Rosenthal, C.D. Fuller, W.H. Morrison, P. Iyer, M.E. Cabanillas, Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF(V600E)-mutated anaplastic thyroid carcinoma. Thyroid 29(8), 1036–1043 (2019)CrossRef
21.
go back to reference M. Kihara, A. Miyauchi, A. Yamauchi, H. Yokomise, Prognostic factors of anaplastic thyroid carcinoma. Surg. Today 34(5), 394–398 (2004)CrossRef M. Kihara, A. Miyauchi, A. Yamauchi, H. Yokomise, Prognostic factors of anaplastic thyroid carcinoma. Surg. Today 34(5), 394–398 (2004)CrossRef
22.
go back to reference N.A. Saeed, J.R. Kelly, H.A. Deshpande, A.K. Bhatia, B.A. Burtness, B.L. Judson, S. Mehra, H.A. Edwards, W.G. Yarbrough, P.R. Peter, E.H. Holt, R.H. Decker, Z.A. Husain, H.S. Park, Adjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancer. Head Neck 42(5), 1031–1044 (2020)CrossRef N.A. Saeed, J.R. Kelly, H.A. Deshpande, A.K. Bhatia, B.A. Burtness, B.L. Judson, S. Mehra, H.A. Edwards, W.G. Yarbrough, P.R. Peter, E.H. Holt, R.H. Decker, Z.A. Husain, H.S. Park, Adjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancer. Head Neck 42(5), 1031–1044 (2020)CrossRef
23.
go back to reference J.W. Park, S.H. Choi, H.I. Yoon, J. Lee, T.H. Kim, J.W. Kim, I.J. Lee, Treatment outcomes of radiotherapy for anaplastic thyroid cancer. Radiat. Oncol. J. 36(2), 103–113 (2018)CrossRef J.W. Park, S.H. Choi, H.I. Yoon, J. Lee, T.H. Kim, J.W. Kim, I.J. Lee, Treatment outcomes of radiotherapy for anaplastic thyroid cancer. Radiat. Oncol. J. 36(2), 103–113 (2018)CrossRef
24.
go back to reference V. Subbiah, R.J. Kreitman, Z.A. Wainberg, J.Y. Cho, J.H.M. Schellens, J.C. Soria, P.Y. Wen, C. Zielinski, M.E. Cabanillas, G. Urbanowitz, B. Mookerjee, D. Wang, F. Rangwala, B. Keam, Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J. Clin. Oncol. 36(1), 7–13 (2018)CrossRef V. Subbiah, R.J. Kreitman, Z.A. Wainberg, J.Y. Cho, J.H.M. Schellens, J.C. Soria, P.Y. Wen, C. Zielinski, M.E. Cabanillas, G. Urbanowitz, B. Mookerjee, D. Wang, F. Rangwala, B. Keam, Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J. Clin. Oncol. 36(1), 7–13 (2018)CrossRef
25.
go back to reference L. Zhang, H. Luo, L. Wang, Y. Liu, S. Rui, Z. Wu, T. Wei, R. Gong, Z. Li, J. Zhu, Diagnostic and prognostic value of preoperative systemic inflammatory markers in anaplastic thyroid cancer. J. Surg. Oncol. 122(5), 897–905 (2020)PubMed L. Zhang, H. Luo, L. Wang, Y. Liu, S. Rui, Z. Wu, T. Wei, R. Gong, Z. Li, J. Zhu, Diagnostic and prognostic value of preoperative systemic inflammatory markers in anaplastic thyroid cancer. J. Surg. Oncol. 122(5), 897–905 (2020)PubMed
Metadata
Title
Risk stratification in patients with anaplastic thyroid carcinoma: role of age
Authors
Mingjun Wang
Tao Wei
Rixiang Gong
Jingqiang Zhu
Zhihui Li
Publication date
24-05-2022
Publisher
Springer US
Published in
Endocrine / Issue 2/2022
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-022-03085-w

Other articles of this Issue 2/2022

Endocrine 2/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.